Journal Scans
Single Nucleotide Polymorphism Associations With Response and Toxic Effects in Patients With Advanced Renal-Cell Carcinoma Treated With First-Line Sunitinib: A Multicentre, Observational, Prospective Study
SNPs Associated With Safety and Efficacy in Sunitinib-Treated Kidney Cancer
J Garcia-Donas, E Esteban, LJ Leandro-Garcia, C Rodriguez-Antona, et al
Yes
20110918
2011 Oct 18
Lancet Oncol
Single Nucleotide Polymorphism Associations With Response and Toxic Effects in Patients With Advanced Renal-Cell Carcinoma Treated With First-Line Sunitinib: A Multicentre, Observational, Prospective Study
Lancet Oncol. 2011 Oct 18;[Epub Ahead of Print], J Garcia-Donas, E Esteban, LJ Leandro-Garcia, C Rodriguez-Antona, et al
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell carcinoma, but some patients do not respond or need dose reductions due to toxicity. Because there are no validated molecular predictors of response or toxicity to sunitinib, we aimed to identify genetic markers predictive of outcome and toxic effects.Methods: In our observational, prospective study we enrolled previously untreated adults (≥18 years) with clear-cell renal-cell carcinoma at 15 institutions in the...
